Roos JC[au] - Search Results

Year	Number of Results
1970	1
1971	3
1972	1
1973	2
1975	1
1976	2
1977	2
1978	1
1979	2
1980	2
1981	5
1982	4
1983	2
1984	5
1985	5
1986	2
1987	1
1988	3
1990	2
1991	4
1992	5
1993	2
1994	6
1995	6
1996	6
1997	4
1998	3
1999	4
2000	6
2001	7
2002	8
2003	8
2004	4
2005	4
2006	7
2007	6
2008	5
2009	3
2010	4
2011	4
2012	4
2013	6
2014	6
2015	6
2016	5
2017	4
2018	10
2019	9
2020	1
2021	2
2022	0

1

Periocular hyaluronic acid fillers: applications, implications, complications.

Murthy R, Roos JCP, Goldberg RA. Murthy R, et al. Among authors: roos jcp. Curr Opin Ophthalmol. 2019 Sep;30(5):395-400. doi: 10.1097/ICU.0000000000000595. Curr Opin Ophthalmol. 2019. PMID: 31261189 Review.

2

Teprotumumab for Active Thyroid Eye Disease.

Roos JCP, Hyry HI, Murthy R. Roos JCP, et al. N Engl J Med. 2020 May 14;382(20):1959. doi: 10.1056/NEJMc2002754. N Engl J Med. 2020. PMID: 32402171 No abstract available.

3

Saving orphan drug legislations: misconceptions and clarifications.

Hyry HI, Cox TM, Roos JC. Hyry HI, et al. Among authors: roos jc. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):111-7. doi: 10.1586/14737167.2016.1141052. Expert Rev Pharmacoecon Outcomes Res. 2016. PMID: 26768506 Review.

4

Brexit and rare diseases: big risk, bigger opportunity?

Hyry HI, Cox TM, Roos JC. Hyry HI, et al. Among authors: roos jc. Curr Med Res Opin. 2017 Apr;33(4):783-784. doi: 10.1080/03007995.2017.1284053. Epub 2017 Mar 9. Curr Med Res Opin. 2017. PMID: 28100081

5

Human glucocerebrosidase mediates formation of xylosyl-cholesterol by β-xylosidase and transxylosidase reactions.

Boer DE, Mirzaian M, Ferraz MJ, Zwiers KC, Baks MV, Hazeu MD, Ottenhoff R, Marques ARA, Meijer R, Roos JCP, Cox TM, Boot RG, Pannu N, Overkleeft HS, Artola M, Aerts JM. Boer DE, et al. Among authors: roos jcp. J Lipid Res. 2021;62:100018. doi: 10.1194/jlr.RA120001043. Epub 2021 Jan 6. J Lipid Res. 2021. PMID: 33361282 Free PMC article.

6

Update on the clinical assessment and management of thyroid eye disease.

Roos JCP, Murthy R. Roos JCP, et al. Curr Opin Ophthalmol. 2019 Sep;30(5):401-406. doi: 10.1097/ICU.0000000000000596. Curr Opin Ophthalmol. 2019. PMID: 31313753 Review.

7

Orphan drugs: expensive yet necessary.

Hyry HI, Roos JC, Cox TM. Hyry HI, et al. Among authors: roos jc. QJM. 2016 May;109(5):361. doi: 10.1093/qjmed/hcv150. Epub 2015 Sep 3. QJM. 2016. PMID: 26337658 Free PMC article. No abstract available.

8

Ophthalmic manifestations of Gaucher disease: the most common lysosomal storage disorder.

Winter AW, Salimi A, Ospina LH, Roos JCP. Winter AW, et al. Among authors: roos jcp. Br J Ophthalmol. 2019 Mar;103(3):315-326. doi: 10.1136/bjophthalmol-2018-312846. Epub 2019 Jan 5. Br J Ophthalmol. 2019. PMID: 30612093 Review.

9

Outrageous prices of orphan drugs: a call for collaboration.

Luzzatto L, Hyry HI, Schieppati A, Costa E, Simoens S, Schaefer F, Roos JCP, Merlini G, Kääriäinen H, Garattini S, Hollak CE, Remuzzi G; Second Workshop on Orphan Drugs participants. Luzzatto L, et al. Among authors: roos jcp. Lancet. 2018 Sep 1;392(10149):791-794. doi: 10.1016/S0140-6736(18)31069-9. Epub 2018 Jul 20. Lancet. 2018. PMID: 30037734 No abstract available.

10

Metabolic myopathies: a guide and update for clinicians.

Burr ML, Roos JC, Ostör AJ. Burr ML, et al. Among authors: roos jc. Curr Opin Rheumatol. 2008 Nov;20(6):639-47. doi: 10.1097/BOR.0b013e328315a05b. Curr Opin Rheumatol. 2008. PMID: 18946322 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results